Key Highlights

  • 22nd Century Group (NASDAQ:XXII) is quoted at USD 0.07, up 6.47%, with 214.68 million shares traded (relative Volume 3.16) and a Market Value of USD 1.42 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Hain Celestial (NASDAQ:HAIN) has until March 22, 2027 to lift its shares back to USD 1.00 under a Nasdaq deadline.
  • Senti Biosciences (NASDAQ:SNTI) holders approved a Merger on October 15, 2026 that involves no cash at closing but offers contingent value rights of up to USD 60.0 million.
  • Context Therapeutics (NASDAQ:CNTX) reported cash of USD 43 million at June 30, 2026, which management says covers operations through the fourth quarter of 2027.

1. 22nd Century Group (NASDAQ:XXII)

Shareholders of 22nd Century Group (NASDAQ:XXII) signed off on August 5, 2026 for a reverse split of up to 1-for-200, intended to meet Nasdaq listing requirements. XXII appears here because the penny stocks screen selects very low share prices, where small orders can move a quote and spreads can be wide. The shareholders also cleared up to USD 30 million of financing, made up of up to USD 20 million of convertible preferred stock with warrants and up to USD 10 million of common stock with warrants. They ratified 3,019,586 inducement warrants issued in June 2026. Published coverage reported an earlier 1-for-15 reverse split announced in January 2026; this is a single source item treated as approximate. This is a small, thinly traded stock, so a few orders can move the quote, spreads can be wide and a gain can fade.

2. Hain Celestial (NASDAQ:HAIN)

On the penny stocks screen, Hain Celestial (NASDAQ:HAIN) shows USD 0.13, up 12.59%, on 2.72 million shares (relative volume 1.35) and a market value of USD 12.20 million, as of the capture on November 4, 2026. For HAIN, the market value and volume matter more than the share price: at a market value of a few million USD, a handful of trades can set the quote. Published coverage of the Annual Report pointed to Debt of about USD 558 million due December 22, 2026, set against about USD 58 million of cash, along with Going Concern doubt; these figures are single source and approximate. The screen shows a loss per share of USD 3.36 and a Neutral rating. Hain Celestial said its shares had closed below USD 1.00 for 30 consecutive Business days, and Nasdaq moved the listing to the Capital Market effective September 24, 2026, with compliance required by March 22, 2027. The core risk is a going concern doubt with debt due on December 22, 2026, plus a quote that can move sharply on small trades.

3. Senti Biosciences (NASDAQ:SNTI)

On the penny stocks screen, Senti Biosciences (NASDAQ:SNTI) shows USD 0.19, up 13.87%, on 896,820 shares and a market value of USD 5.86 million, as of the capture on November 4, 2026. SNTI appears here because the penny stocks screen selects very low share prices, where modest orders can push a quote and spreads can be wide. Stockholders also approved a reverse split at a ratio between 1-for-20 and 1-for-50. Convertible notes mature on November 23, 2026 at 200% of principal and are expected to convert into about 46.8 million shares at USD 0.342. This is a small, thinly traded stock, so a few orders can move the quote, spreads can be wide and a gain can fade.

4. Acumen Pharmaceuticals (NASDAQ:ABOS)

On the penny stocks screen, Acumen Pharmaceuticals (NASDAQ:ABOS) shows USD 0.24, up 14.09%, on 33.72 million shares (relative volume 4.42) and a market value of USD 17.34 million, as of the capture on November 4, 2026. A sub-USD 1 price does not settle the question of the business, though it can bring Listing Rules into play, including the Nasdaq minimum bid price, and make new financing dilutive for ABOS holders. Published coverage reported a one-day drop of about 91% on October 30; this is a single source figure treated as approximate, which would make the latest gain a rebound from a very depressed level. The screen's market value of USD 17.34 million sits below the USD 78.6 million cash figure, a simple comparison across a screen figure and a reported one. At this scale a handful of trades can shift the price, spreads can be wide and quoted moves can flip, so a rise tells us nothing about what follows.

5. Context Therapeutics (NASDAQ:CNTX)

On the penny stocks screen, Context Therapeutics (NASDAQ:CNTX) shows USD 0.20, up 6.82%, on 1.29 million shares (relative volume 1.07) and a market value of USD 18.56 million, as of the capture on November 4, 2026. For CNTX, the market value and volume matter more than the share price: at a market value of a few million USD, a handful of trades can set the quote. Its lead candidate, CTIM-76, earned FDA Fast Track Designation in April 2026, and a Phase 1b expansion is anticipated to begin in the first quarter of 2027. Published coverage reported a close of USD 0.69 on August 5, 2026, followed by a fall of 23.06% to USD 0.53 in overnight trading; both are single source figures treated as approximate. At this scale a modest number of orders can shift the price, spreads can be wide and quoted moves can reverse, so an advance tells nothing about the next step.

Where Things Stand

Do not take that for granted. 22nd Century Group (NASDAQ:XXII) holds authority for a reverse split of up to 1-for-200, HAIN faces a Nasdaq deadline of March 22, 2027, SNTI has convertible notes maturing on November 23, 2026, and ABOS is rebounding from a fall of about 91% reported by a single source, so each gain sits on a fragile base. Penny names are cheap per share but not necessarily cheap for the business: market values of a few million USD, going concern doubts and maturing notes recur across this screen, which makes it as much a map of risk as of opportunity.